Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC
Year: 2018
Type: article
Abstract: Though the RV144 phase III clinical trial showed promise that an effective vaccine against HIV-1 is possible, a successful vaccine will require improvement over the vaccine candidate (ALVAC) used in the RV144 study. With that goal in mind, we have tested in nonhuman primates an attenuated but replication-competent vector, NYVAC-KC, in direct comparison to its parental vector, NYVAC, which is replication restricted in human cells, similar to the ALVAC vector used in RV144. We have utilized a prime-boost regimen for administration of the vaccine candidate that is similar to the one used in the RV144 study. The results of this study indicate that a replication-competent poxvirus vector may improve upon the effectiveness of the RV144 clinical trial vaccine candidate.
Source: Journal of Virology
DOI: 10.1128/jvi.01513-18
Authors: Karen V. Kibler, Benedikt Asbach, Beatriz Perdiguero, Juan García-Arriaza, Nicole L. Yates, Robert Parks, Sherry Stanfield-Oakley, Guido Ferrari, David C. Montefiori, Georgia D. Tomaras, Mario Roederer, Kathryn E. Foulds, Donald N. Forthal, Michael S. Seaman, Steve Self, Raphael Gottardo, Sanjay Phogat, James Tartaglia, Susan Barnett, Anthony D. Cristillo, Deborah Weiss, Lindsey Galmin, Song Ding, Jonathan L. Heeney, Mariano Esteban, Ralf Wagner, Giuseppe Pantaleo, Bertram L. Jacobs
Institutions: Arizona State University, Institute of Medical Microbiology and Hygiene, University of Regensburg, Consejo Superior de Investigaciones Científicas, Centro Nacional de Biotecnología, Duke Medical Center, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Vaccine Research Center, University of California, Irvine, Beth Israel Deaconess Medical Center, Fred Hutch Cancer Center, Advanced Bioscience Laboratories (United States), Eurovacc Foundation, University of Cambridge, Centre Hospitalier Universitaire Vaudois, University of Lausanne
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,478
Awards: Fred Hutchinson Cancer Research Center - to establish a vaccine immunology statistical center that will provide statistical and data management support to the Vaccine Discovery Centers, Institute for Clinical and Translational Science, G3848097742, Foundation for the National Institutes of Health (FNIH) - to facilitate HIV vaccine discovery and eventual licensure through provision of standardized and qualified assays to assess T cell immunogenicity i..., The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection, Duke University - to facilitate the discovery of a safe, effective and practical HIV-1 vaccine by using valid laboratory criteria and Good Clinical Laboratory Practi...
OpenAlex ID: W2901657515